ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate. These key neurotransmitters – known to regulate mood, behaviour, and bodily functions – have served as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results